Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

Hitoshi Suzuki, Run Fan, Zhixin Zhang, Rhubell Brown, Stacy Hall, Bruce A. Julian, W. Winn Chatham, Yusuke Suzuki, Robert J. Wyatt, Zina Moldoveanu, Jeannette Y. Lee, James Robinson, Milan Tomana, Yasuhiko Tomino, Jiri Mestecky, Jan Novak

Research output: Contribution to journalArticle

254 Citations (Scopus)

Abstract

IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit in the glomerular mesangium and induce the mesangioproliferative glomerulonephritis characteristic of IgAN. To define the precise specificities and molecular properties of the IgG antibodies, we generated EBV-immortalized IgG-secreting lymphocytes from patients with IgAN and found that the secreted IgG formed complexes with galactose-deficient IgA1 in a glycan-dependent manner. We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients. Furthermore, site-directed mutagenesis that reverted the residue to alanine reduced the binding of recombinant IgG to galactose-deficient IgA1. Finally, we developed a dot-blot assay for the glycan-specific IgG antibody that differentiated patients with IgAN from healthy and disease controls with 88% specificity and 95% sensitivity and found that elevated levels of this antibody in the sera of patients with IgAN correlated with proteinuria. Collectively, these findings indicate that glycan-specific antibodies are associated with the development of IgAN and may represent a disease-specific marker and potential therapeutic target.

Original languageEnglish (US)
Pages (from-to)1668-1677
Number of pages10
JournalJournal of Clinical Investigation
Volume119
Issue number6
DOIs
StatePublished - Jun 1 2009

Fingerprint

Immunoglobulin A
Immunoglobulin G
Antibodies
Galactose
Polysaccharides
Antigen-Antibody Complex
Glomerular Mesangium
Complementarity Determining Regions
Glomerulonephritis
Site-Directed Mutagenesis
Human Herpesvirus 4
Proteinuria
Alanine
Lymphocytes
Light
Antigens
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. / Suzuki, Hitoshi; Fan, Run; Zhang, Zhixin; Brown, Rhubell; Hall, Stacy; Julian, Bruce A.; Chatham, W. Winn; Suzuki, Yusuke; Wyatt, Robert J.; Moldoveanu, Zina; Lee, Jeannette Y.; Robinson, James; Tomana, Milan; Tomino, Yasuhiko; Mestecky, Jiri; Novak, Jan.

In: Journal of Clinical Investigation, Vol. 119, No. 6, 01.06.2009, p. 1668-1677.

Research output: Contribution to journalArticle

Suzuki, H, Fan, R, Zhang, Z, Brown, R, Hall, S, Julian, BA, Chatham, WW, Suzuki, Y, Wyatt, RJ, Moldoveanu, Z, Lee, JY, Robinson, J, Tomana, M, Tomino, Y, Mestecky, J & Novak, J 2009, 'Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity', Journal of Clinical Investigation, vol. 119, no. 6, pp. 1668-1677. https://doi.org/10.1172/JCI38468
Suzuki, Hitoshi ; Fan, Run ; Zhang, Zhixin ; Brown, Rhubell ; Hall, Stacy ; Julian, Bruce A. ; Chatham, W. Winn ; Suzuki, Yusuke ; Wyatt, Robert J. ; Moldoveanu, Zina ; Lee, Jeannette Y. ; Robinson, James ; Tomana, Milan ; Tomino, Yasuhiko ; Mestecky, Jiri ; Novak, Jan. / Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 6. pp. 1668-1677.
@article{e90bb605550d467fa139a3b0701daaf6,
title = "Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity",
abstract = "IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit in the glomerular mesangium and induce the mesangioproliferative glomerulonephritis characteristic of IgAN. To define the precise specificities and molecular properties of the IgG antibodies, we generated EBV-immortalized IgG-secreting lymphocytes from patients with IgAN and found that the secreted IgG formed complexes with galactose-deficient IgA1 in a glycan-dependent manner. We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients. Furthermore, site-directed mutagenesis that reverted the residue to alanine reduced the binding of recombinant IgG to galactose-deficient IgA1. Finally, we developed a dot-blot assay for the glycan-specific IgG antibody that differentiated patients with IgAN from healthy and disease controls with 88{\%} specificity and 95{\%} sensitivity and found that elevated levels of this antibody in the sera of patients with IgAN correlated with proteinuria. Collectively, these findings indicate that glycan-specific antibodies are associated with the development of IgAN and may represent a disease-specific marker and potential therapeutic target.",
author = "Hitoshi Suzuki and Run Fan and Zhixin Zhang and Rhubell Brown and Stacy Hall and Julian, {Bruce A.} and Chatham, {W. Winn} and Yusuke Suzuki and Wyatt, {Robert J.} and Zina Moldoveanu and Lee, {Jeannette Y.} and James Robinson and Milan Tomana and Yasuhiko Tomino and Jiri Mestecky and Jan Novak",
year = "2009",
month = "6",
day = "1",
doi = "10.1172/JCI38468",
language = "English (US)",
volume = "119",
pages = "1668--1677",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

AU - Suzuki, Hitoshi

AU - Fan, Run

AU - Zhang, Zhixin

AU - Brown, Rhubell

AU - Hall, Stacy

AU - Julian, Bruce A.

AU - Chatham, W. Winn

AU - Suzuki, Yusuke

AU - Wyatt, Robert J.

AU - Moldoveanu, Zina

AU - Lee, Jeannette Y.

AU - Robinson, James

AU - Tomana, Milan

AU - Tomino, Yasuhiko

AU - Mestecky, Jiri

AU - Novak, Jan

PY - 2009/6/1

Y1 - 2009/6/1

N2 - IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit in the glomerular mesangium and induce the mesangioproliferative glomerulonephritis characteristic of IgAN. To define the precise specificities and molecular properties of the IgG antibodies, we generated EBV-immortalized IgG-secreting lymphocytes from patients with IgAN and found that the secreted IgG formed complexes with galactose-deficient IgA1 in a glycan-dependent manner. We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients. Furthermore, site-directed mutagenesis that reverted the residue to alanine reduced the binding of recombinant IgG to galactose-deficient IgA1. Finally, we developed a dot-blot assay for the glycan-specific IgG antibody that differentiated patients with IgAN from healthy and disease controls with 88% specificity and 95% sensitivity and found that elevated levels of this antibody in the sera of patients with IgAN correlated with proteinuria. Collectively, these findings indicate that glycan-specific antibodies are associated with the development of IgAN and may represent a disease-specific marker and potential therapeutic target.

AB - IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit in the glomerular mesangium and induce the mesangioproliferative glomerulonephritis characteristic of IgAN. To define the precise specificities and molecular properties of the IgG antibodies, we generated EBV-immortalized IgG-secreting lymphocytes from patients with IgAN and found that the secreted IgG formed complexes with galactose-deficient IgA1 in a glycan-dependent manner. We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients. Furthermore, site-directed mutagenesis that reverted the residue to alanine reduced the binding of recombinant IgG to galactose-deficient IgA1. Finally, we developed a dot-blot assay for the glycan-specific IgG antibody that differentiated patients with IgAN from healthy and disease controls with 88% specificity and 95% sensitivity and found that elevated levels of this antibody in the sera of patients with IgAN correlated with proteinuria. Collectively, these findings indicate that glycan-specific antibodies are associated with the development of IgAN and may represent a disease-specific marker and potential therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=67651006853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651006853&partnerID=8YFLogxK

U2 - 10.1172/JCI38468

DO - 10.1172/JCI38468

M3 - Article

VL - 119

SP - 1668

EP - 1677

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -